Novel molecular targets for urothelial carcinoma.

ABSTRACT:

Introduction

Urothelial cancer (UC) remains a significant public health problem, with no new second-line agents FDA-approved in the US. Next-generation sequencing technologies are starting to generate a molecular landscape of UC thus revealing novel molecular targets.

Areas covered

In this review, the authors provide a detailed review of novel molecular targets in UC based on published genomic analyses of urothelial tumors. We provide an overview of each molecular target with a brief discussion of therapeutic strategies and clinical trials targeting each pathway.

Expert opinion

UC continues to be a lethal disease with no FDA-approved effective second-line therapies. Platinum resistance continues to be a daunting clinical problem. Next-generation sequencing methods hav

SUBMITTER: Faltas BM 

PROVIDER: S-EPMC4406627 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature